Evolutional changes in maintenance immunosuppression following heart transplantation

Area of Science:

• Cardiology
• Immunology
• Pharmacology

Background:

• Heart transplant (HT) recipients frequently require adjustments to their immunosuppressive maintenance medications.
• Standard immunosuppression typically involves an anticalcineurin agent, an antimetabolite, and a steroid.

Purpose of the Study:

• To quantify the incidence and causes of immunosuppressive medication changes in heart transplant patients.
• To describe the patterns and timing of these medication alterations.

Main Methods:

• A descriptive study analyzed 432 heart transplants performed between November 1987 and October 2005.
• Baseline and maintenance immunosuppressive regimens were compared.
• Kaplan-Meier survival analysis was employed.

Main Results:

• The most notable medication change was switching from azathioprine to mycophenolate mofetil.
• The 17-year survival rate for heart transplant recipients was 66%.

Conclusions:

• There is a documented decrease in the use of cyclosporine and azathioprine, with a corresponding increase in tacrolimus and mycophenolate mofetil, aligning with international trends.
• Steroid use has remained consistent.
• These shifts indicate a move towards immunosuppressive agents with improved safety profiles for heart transplant recipients.